Is Ewing's Sarcoma a Stem Cell Tumor?

Abstract Background: Several studies have shown that Pegfilgrastim, the long acting agent of rh-GCSF, is as effective as Filgrastim in children undergoing cytotoxic chemotherapy by reducing the duration of neutropenia without increased adverse events as bone pain and headache. Recent studies in adults have shown that Pegfilgrastim is also effective to mobilize CD 34+ stem cells. In contrast to Filgrastim studies showed a reduction of time to reach the peripheral blood CD 34+ cell peak, resulting in earlier performance of leukapheresis. Although the use of Pegfilgrastim in children after conventional chemotherapy is established, only few data have been published yet describing the ability to mobilize CD 34+ stem cells. The aim of the study was to compare the efficacy of Pegfilgrastim versus Filgrastim for CD 34+ stem cell mobilization in children and adolescents. Methods: Patients admitted after 2006 were stimulated with Pegfilgrastim on day 4 following a chemotherapy course of the according treatment protocol followed by peripheral stem-cell-apheresis. Filgrastim was added when CD 34 + stem cells did not reach 15/μl between day 15 to 20. Patients were compared to historical controls (2002–2005) stimulated with conventional daily Filgrastim. Results: 3 groups of patients were compared: Group 1 (historical group): 6 patients with Ewing’s Sarcoma undergoing chemotherapy according to the EURO-EWING protocol receiving Filgrastim 10–20 μg/kg (median 11 μg/kg) underwent a median of 3,8 peripheral stem cell collections (PSCC) between day 12–24 (median 15,4). A median of 16,9 CD 34+ stem cells/kg BW were collected. Group 2: 3 Patients with Ewing’s Sarcoma admitted after 2006 undergoing chemotherapy according to the EURO-EWING protocol received only Pegfilgrastim 100–200 μg/kg (median 166 μg/kg). 3 PSCC were performed between day 11–13 (median 12) and a median of 24,3 CD 34+ stem cells/kg BW were collected. Group 3: 5 Patients suffering from recurrent neoplasm [B-NHL (n=1), medulloblastoma (n=1), ependymoma (n=1) and germ cell tumor (n=2)]. Chemotherapy was performed according to relapse protocols followed by Pegfilgrastim 150–200μg/kg (median 188 μg/kg), however 2 patients needed further cytokine stimulation with Filgrastim 10–15μg/kg (median 12,5 μg/kg) combined with stem cell factor. A median of 3,2 PSCC was performed between day 8–30 (median 17). A median of 11,9 CD 34+ stem cells/kg BW were collected. Discussion: Our data show that stem cell mobilisation with Pegfilgrastim seems to produce earlier CD34+ peaks and better CD34+ yields than Filgrastim in children when performed during primary or without previous long lasting chemotherapy. However patients with previous long lasting chemotherapy might need additional mobilisation therapy with Filgrastim and/or stem cell factor.

Download Full-text

1201 Consolidation with Busulfan and Melphalan followed by hematopoietic stem-cell transplantation (SCT) in children with poor prognosis Ewing's sarcoma

European Journal of Cancer ◽

10.1016/0959-8049(95)96447-l ◽

1995 ◽

Vol 31 ◽

pp. S250 ◽

Cited By ~ 1

Author(s):

D. Valteau-Couanet ◽

E. Benhamou ◽

O. Oberlin ◽

D. Couanet ◽

V. Lapierre ◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Poor Prognosis ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Hematopoietic Stem

Download Full-text

Extraskeletal Ewing's Sarcoma Occurring as a Mass in the Neck

Otolaryngology ◽

10.1177/019459988209000422 ◽

1982 ◽

Vol 90 (4) ◽

pp. 491-493 ◽

Cited By ~ 9

Author(s):

Ray O. Gustafson ◽

Nicolas E. Maragos ◽

Herbert M. Reiman

Keyword(s):

Young Adults ◽

Radiation Therapy ◽

Stem Cell ◽

Surgical Treatment ◽

Mesenchymal Stem Cell ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Malignant Neoplasm ◽

Aggressive Therapy ◽

Extraskeletal Ewing’S Sarcoma

Extraskeletal Ewing's sarcoma is a rare malignant neoplasm. Arising from a primitive mesenchymal stem cell and primarily affecting young adults, this lesion demands aggressive therapy, including surgical treatment, radiation therapy, and chemotherapy.

Download Full-text

High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre

Sarcoma ◽

10.1155/2004/329273 ◽

2004 ◽

Vol 8 (2-3) ◽

pp. 63-69 ◽

Cited By ~ 1

Author(s):

Sébastien J. Hotte ◽

Anne M. Smith ◽

Vivien H.C. Bramwell ◽

Kang Howson-Jan

Keyword(s):

Stem Cell ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Residual Disease ◽

High Dose Chemotherapy ◽

High Dose ◽

Cell Transplant ◽

Alive With Disease ◽

Risk Patients ◽

Time To Relapse

Purpose: Few reports have been published on the evaluation of stem cell auto transplantation for chemosensitive sarcomas. Some suggest benefit, others do not. We present results of 24 patients with sarcoma undergoing autotransplantation at a Canadian institution.Patients and Methods: Twenty-four patients were treated between 1988 and 1998: 23 were ≥18 years (median 27; range 12–56); genders were equal; 12 patients had Ewing's sarcoma. At diagnosis, 12 (50%) had metastatic disease. Prior to autotransplant, all had ≥1 chemotherapy regimen. Fourteen (58%) were in complete remission (CR) and seven (29%) had minimal residual disease. All received etoposide 60 mg/kg (Day –4), melphalan 140 mg/m2on (Day –3) and a stem cell reinfusion (Day 0).Results: Three patients (12.5%) were alive and disease-free with median follow-up of 92 months (80–142); one was alive with disease 32 months post-autotransplant. Twenty had died (disease, 17; transplant-related, 2; unknown, 1). Of the four alive, three had Ewing's sarcoma, one alveolar rhabdomyosarcoma, and all were in CR at transplant. Median time to relapse was 6 months (2–59). Sixteen of 18 (89%) relapsed within 1 year. Median overall survival was 10 months (0–137). A trend towards improved survival (P=0.07) was evident for patients in CR prior to autotransplant.Conclusions: Stem cell autotransplantation does not benefit most patients with sarcoma. A subgroup of high-risk patients in CR may fare better and warrant further study.

Download Full-text

Pediatric cancers in Bihar: A retrospective tertiary cancer center study

South Asian Journal of Cancer ◽

10.4103/sajc.sajc_48_19 ◽

2020 ◽

Vol 09 (01) ◽

pp. 53-55 ◽

Cited By ~ 2

Author(s):

Avinash Pandey ◽

Anjana Singh ◽

Vijendra Kumar ◽

Jayant Prakash ◽

Ritesh Ranu ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumor ◽

Pediatric Cancer ◽

Hodgkin’S Lymphoma ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Wilms Tumor ◽

Cell Tumor ◽

Hodgkin's Lymphoma ◽

Pediatric Cancers

Abstract Background: There is lack of information regarding pattern of distribution of pediatric cancers in Bihar. Aim: The aim of this study is to identify the pattern of distribution of pediatric cancers. Objectives: To analyze demographic data, type, and pattern of pediatric cancers in Bihar by retrospective clinical audit. Materials and Methods: All individual consecutive patients between ages 0 and 18 years registered in the Department of Medical and Pediatric Oncology from January 1, 2018 till December 31, 2018, were enrolled in this study. Data pertaining to age, sex, and type of cancer were retrieved from clinical database by retrospective audit and stratified into hematolymphoid and solid pediatric cancer cohorts. Frequency distribution and descriptive statistics were used to analyze the data using SPSS version 17.0. Results: A total of 247 pediatric cancers were registered, of which 142/247 (57%) and 15/247 (43%) were pediatric hematolymphoid and solid cancers, respectively. The median age was 9 years, while male-to-female ratio was 2.26. Acute lymphoblastic leukemia (ALL), 76/247 (31%) was the most common pediatric cancer overall. Hodgkin's lymphoma, 27/142 (19%) was the second most common hematolymphoid malignancy, after ALL was 76/142 (54%). Among solid tumors, Wilms' tumor was the most common, 28/105 (27%) followed by Ewing's sarcoma, 16/105 (15%), and germ cell tumor, 15/105 (14%). Central nervous system malignancies were among the least common solid tumor cancers, 3/105 (3%). Conclusion: ALL and Hodgkin's lymphoma are the most common pediatric cancers. Among solid malignancies, Wilms tumor, Ewing's sarcoma, and Germ cell tumor are predominant.

Download Full-text